Evonik has developed a patented biotechnological green production process based on the fermentation of a nonconventional yeast called Wickerhamomyces ciferrii (formerly known as Pichia ciferrii).
This yeast produces high amounts of the ceramide precursor phytosphingosine, which is secreted into the growth medium, extracted and further converted into a range of ceramides marketed as valuable cosmetic ingredients. The ceramide biosynthesis pathway is conserved from yeast to man. Therefore, Evonik’s ceramides have the same stereochemical conformation as the ceramides in our skin, i.e. they are truly skinidentical. The next step was to analyse the genome sequence of Wickerhamomyces ciferrii which will help to get valuable information for the general understanding of sphingolipid biosynthesis. This will likely pave the way for the development of tailor-made yeast strains with improved sphingolipid production capabilities. Scientists from Evonik’s Consumer Specialties business unit, together with colleagues from the Science-to-Business Center Biotechnology and collaboration partners from academia, recently determined the draft Wickerhamomyces ciferrii genome sequence. The project was funded by the Federal Ministry of Education and Research (BMBF). The genome sequence was just published in the peer-reviewed journal Eukaryotic Cell [Schneider et al., Eukaryotic Cell 2012; 11 (12): 1582].
